A nasal medication based on a commonly used blood-thinning drug could reduce transmission of COVID-19 in homes and hospitals and will soon begin clinical trials in Victoria, the state’s government announced today.
Treasurer, Tim Pallas met with researchers at Monash University’s Medicines Manufacturing Innovation Centre (MMIC) in Clayton today to discuss preparations to trial the ground-breaking COVID-19 nasal spray later this year.
If the trials prove effective, heparin spray could quickly and easily be delivered with quick pumps in high-risk COVID settings such as medical wards or in the homes of COVID contacts, to reduce illness and transmission.
COVID-19 first infects the nose before spreading to the body, if there is not a strong enough immune response. By coating the virus’s spike protein with heparin the virus is not able to penetrate into the cells of the nose and replicate. This will have the effect of reducing viral load and potential spread of the virus within the body.
Heparin is the second most widely used drug in the world and is primarily prescribed as a blood-thinner to treat or prevent blood clots.
The six-month clinical trial is being led by the Murdoch Children’s Research Institute, University of Melbourne, St Vincent’s Hospital, Doherty Institute and Monash University, in collaboration with Oxford University.
It is being funded by $4.2 million from the Victorian Government’s COVID-19 Research Fund.
Patient recruitment is set to commence in the coming months through Northern Health, with people presenting with respiratory conditions, who will then be tested for COVID and offered the treatment if they test positive.
The trial will involve approximately 400 households.
If the trial yields positive results, Monash University’s MMIC will prepare a business case to investigate the potential for local manufacture in Victoria.
